Avadel Pharmaceuticals: Strong Launch Of Lumryz With A Legal Risk Backdrop

vlada_maestro/iStock via Getty Images Shares of Avadel Pharmaceuticals (NASDAQ:AVDL) made little progress since the launch of Lumryz in June 2023 despite the product's good commercial uptake. The company announced in early January that approximately 1,900 patients were enrolled in the RYZUP hub at the end of 2023, that over 1,000 are already on Lumryz, and that Q4 net sales were $19 million. These are still the early days of the launch, but the numbers are very encouraging with what looks like good exec ...